Philip Morris Q1 earnings face FDA scrutiny on nicotine pouches amid growth and regulatory challenges.

Philip Morris International will report Q1 2026 earnings on April 22, with investor focus on FDA regulatory scrutiny of its nicotine pouch brand ZYN. Despite strong growth—ZYN U.S. shipments rose 37% in 2025 and the company holds about 70% of the U.S. market—FDA concerns over youth access and slow product approvals may hinder momentum. The company also faces margin pressure from promotional spending and currency headwinds. This quarter is pivotal to see if regulatory delays and competitive pressures will slow the smoke-free product's growth, which is central to Philip Morris's long-term strategy.